Yang, Huiqin; Craig, Dawn; Epstein, David; Bojke, Laura; … - In: PharmacoEconomics 30 (2012) 4, pp. 257-270
-to-head. To compare the effectiveness of the biologics etanercept, infliximab, adalimumab and golimumab, the manufacturer … treatments in 'Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis' (NICE clinical guideline 199); and … biologics were considered equally effective, then etanercept, adalimumab and golimumab had almost equal costs and equal QALYs …